CL2012001745A1 - Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras - Google Patents

Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras

Info

Publication number: CL2012001745A1
Authority: CL; Chile
Prior art keywords: epoc; psoriasis; asthma; pharmaceutical composition; treatment
Prior art date: 2009-12-23

Application number

CL2012001745A

Other languages

English (en)

Inventor

Yasuyoshi Arikawa

Benjamin Jones

Betty Lam

Zhe Nie

Christopher Smith

Masashi Takahashi

Qing Dong

Victoria Feher

Original Assignee

Takeda Pharmaceuticals Company Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-23

Filing date

2012-06-25

Publication date

2014-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43618073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001745(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-25 Application filed by Takeda Pharmaceuticals Company Ltd filed Critical Takeda Pharmaceuticals Company Ltd

2014-07-18 Publication of CL2012001745A1 publication Critical patent/CL2012001745A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)

CL2012001745A 2009-12-23 2012-06-25 Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras CL2012001745A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28996909P	2009-12-23	2009-12-23
US38696410P	2010-09-27	2010-09-27

Publications (1)

Publication Number	Publication Date
CL2012001745A1 true CL2012001745A1 (es)	2014-07-18

Family

ID=43618073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012001745A CL2012001745A1 (es)	2009-12-23	2012-06-25	Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras

Country Status (42)

Country	Link
US (7)	US9181255B2 (es)
EP (4)	EP2516434B1 (es)
JP (7)	JP5658274B2 (es)
KR (1)	KR101790255B1 (es)
CN (1)	CN102753548B (es)
AR (1)	AR081797A1 (es)
AU (1)	AU2010333804B2 (es)
BR (1)	BR112012015651B1 (es)
CA (1)	CA2786950C (es)
CL (1)	CL2012001745A1 (es)
CO (1)	CO6592058A2 (es)
CR (1)	CR20120392A (es)
CY (1)	CY1116736T1 (es)
DK (1)	DK2516434T3 (es)
DO (1)	DOP2012000180A (es)
EA (1)	EA021568B1 (es)
EC (1)	ECSP12012057A (es)
ES (1)	ES2545616T3 (es)
GE (1)	GEP20156243B (es)
HR (1)	HRP20150878T1 (es)
HU (1)	HUE025177T2 (es)
IL (1)	IL220509A (es)
JO (1)	JO3108B1 (es)
MA (1)	MA33909B1 (es)
ME (1)	ME02186B (es)
MX (1)	MX2012007402A (es)
MY (1)	MY159257A (es)
NZ (1)	NZ601267A (es)
PE (1)	PE20130188A1 (es)
PH (1)	PH12012501311A1 (es)
PL (1)	PL2516434T3 (es)
PT (1)	PT2516434E (es)
RS (1)	RS54180B1 (es)
SG (1)	SG181857A1 (es)
SI (1)	SI2516434T1 (es)
SM (1)	SMT201500199B (es)
TN (1)	TN2012000316A1 (es)
TW (1)	TWI457339B (es)
UA (1)	UA107100C2 (es)
UY (1)	UY33151A (es)
WO (1)	WO2011079051A1 (es)
ZA (1)	ZA201205428B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2516434E (pt)	2009-12-23	2015-10-05	Takeda Pharmaceutical	Pirrolidinonas heteroaromáticas fundidas como inibidores de syk
BR112013024901A2 (pt) *	2011-03-28	2017-11-07	Hoffmann La Roche	compostos de tiazolopirimidina
EP2723739B1 (en)	2011-06-22	2016-08-24	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives
EP2900243A4 (en)	2012-09-27	2016-04-13	Portola Pharm Inc	BICYCLIC OXA LACTAM KINASE HEMMER
EP2900639B1 (en) *	2012-09-27	2017-08-16	Portola Pharmaceuticals, Inc.	Bicyclic dihydropyridone kinase inhibitors
DK2914296T4 (da)	2012-11-01	2022-01-03	Infinity Pharmaceuticals Inc	Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
WO2014151386A1 (en)	2013-03-15	2014-09-25	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014194254A1 (en)	2013-05-30	2014-12-04	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
JP6159028B2 (ja) *	2013-07-31	2017-07-05	ギリアードサイエンシーズ，インコーポレイテッド	Ｓｙｋ阻害剤
ES2900806T3 (es)	2013-10-04	2022-03-18	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
UY35898A (es)	2013-12-23	2015-07-31	Gilead Sciences Inc	?compuestos inhibidores de syk y composiciones que los comprenden?.
AU2015222865B2 (en)	2014-02-28	2019-06-20	Takeda Pharmaceutical Company Limited	TYK2 inhibitors and uses thereof
SG10201808053XA (en)	2014-03-19	2018-10-30	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10245262B2 (en)	2014-04-01	2019-04-02	The University Of Queensland	Immunological reagents and uses therefor
WO2015160986A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
EP3134439B1 (en)	2014-04-21	2018-12-26	Millennium Pharmaceuticals, Inc.	Anti-psyk antibody molecules and use of same for syk-targeted therapy
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3227297B1 (en) *	2014-12-05	2021-01-20	Array Biopharma, Inc.	4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
MY199935A (en)	2014-12-18	2023-11-29	Wells Therapeutics Inc	Solid state forms of fused heteroaromatic pyrrolidinones
US20160251376A1 (en) *	2015-02-27	2016-09-01	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
EP3344624B8 (en) *	2015-09-02	2023-11-29	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors and uses thereof
JP6980649B2 (ja)	2015-09-14	2021-12-15	インフィニティーファーマシューティカルズ，インコーポレイテッド	イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
GB201604970D0 (en)	2016-03-23	2016-05-04	Syngenta Participations Ag	Improvements in or relating to organic compounds
WO2017205801A1 (en) *	2016-05-27	2017-11-30	Takeda Pharmaceutical Company Limited	Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
ES2993451T3 (en)	2016-06-13	2024-12-30	Glaxosmithkline Ip Dev Ltd	Substituted pyridines as inhibitors of dnmt1
CA3028718A1 (en)	2016-06-24	2017-12-28	Infinity Pharmaceuticals, Inc.	Combination therapies
CA3030630A1 (en) *	2016-07-13	2018-01-18	Takeda Pharmaceutical Company Limited	Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
US10111882B2 (en)	2016-09-14	2018-10-30	Gilead Sciences, Inc.	SYK inhibitors
TW201822764A (zh)	2016-09-14	2018-07-01	美商基利科學股份有限公司	Syk抑制劑
WO2018195471A1 (en)	2017-04-21	2018-10-25	Gilead Sciences, Inc.	Syk inhibitors in combination with hypomethylating agents
ES2906205T3 (es) *	2017-06-14	2022-04-13	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Inhibidor de Syk y método de uso para el mismo
TWI782056B (zh) *	2017-07-14	2022-11-01	日商鹽野義製藥股份有限公司	具有ｍｇａｔ２抑制活性的縮合環衍生物
CN110267954B (zh) *	2017-09-28	2022-05-10	上海海雁医药科技有限公司	苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
KR20190043437A (ko)	2017-10-18	2019-04-26	씨제이헬스케어 주식회사	단백질 키나제 억제제로서의 헤테로고리 화합물
AU2018350683A1 (en) *	2017-10-19	2020-04-02	Bayer Animal Health Gmbh	Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019088039A1 (en)	2017-10-30	2019-05-09	Takeda Pharmaceutical Company Limited	Treatment of acute myeloid leukemia
WO2020073945A1 (zh) *	2018-10-10	2020-04-16	江苏豪森药业集团有限公司	双环类衍生物抑制剂、其制备方法和应用
KR102195348B1 (ko)	2018-11-15	2020-12-24	에이치케이이노엔 주식회사	단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
JP7608166B2 (ja)	2019-01-11	2025-01-06	塩野義製薬株式会社	Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体
AU2020225455A1 (en) *	2019-02-22	2021-09-09	Kronos Bio, Inc.	Solid forms of condensed pyrazines as Syk inhibitors
JP2022505053A (ja) *	2019-03-18	2022-01-14	上海海雁医薬科技有限公司	Ｂｔｋ阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN116096369B (zh) *	2020-09-01	2025-09-16	上海海雁医药科技有限公司	布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
WO2022127753A1 (zh) *	2020-12-18	2022-06-23	山东轩竹医药科技有限公司	稠环类AhR抑制剂
WO2022165530A1 (en) *	2021-02-01	2022-08-04	Janssen Biotech, Inc.	Small molecule inhibitors of salt inducible kinases
CN117120090A (zh)	2021-02-12	2023-11-24	林伯士萨顿公司	Hpk1拮抗剂和其用途
JP2024509192A (ja)	2021-03-05	2024-02-29	ニンバスサターン，インコーポレイテッド	Ｈｐｋ１アンタゴニスト及びその使用
WO2022213062A1 (en) *	2021-03-29	2022-10-06	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
JP2024540296A (ja) *	2021-11-04	2024-10-31	レデックス・ファーマ・リミテッド	線維症
CN114907992B (zh)	2022-05-18	2023-06-16	塔里木大学	拮抗植物病原菌的菌株c11及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63107966A (ja)	1986-05-22	1988-05-12	Fujisawa Pharmaceut Co Ltd	ピリミジン誘導体
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5272158A (en)	1991-10-29	1993-12-21	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5238950A (en) *	1991-12-17	1993-08-24	Schering Corporation	Inhibitors of platelet-derived growth factor
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6432963B1 (en)	1997-12-15	2002-08-13	Yamanouchi Pharmaceutical Co., Ltd.	Pyrimidine-5-carboxamide derivatives
AU2095099A (en)	1997-12-23	1999-07-12	Alcon Laboratories, Inc.	Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
DE60017898T2 (de)	1999-06-09	2006-01-12	Yamanouchi Pharmaceutical Co., Ltd.	Neuartige heterocyclische carboxamidderivate
GB9918035D0 (en) *	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
FR2796946A1 (fr)	1999-07-30	2001-02-02	Aventis Pharma Sa	Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique
BR0016415A (pt)	1999-12-16	2002-12-24	Alcon Inc	Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
DE60118521T2 (de) *	2000-01-07	2006-10-12	Universitaire Instelling Antwerpen	Purin derivate, ihre herstellung und verwendung
AU2001232271A1 (en)	2000-02-14	2001-08-20	Japan Tobacco Inc.	Preventives/remedies for postoperative stress
JP2001302667A (ja)	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US7105667B2 (en)	2001-05-01	2006-09-12	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) *	2001-05-01	2002-11-07	Bristol-Myers Squibb Company	Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) *	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003009852A1 (en)	2001-07-24	2003-02-06	Merck & Co., Inc.	Tyrosine kinase inhibitors
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) *	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
RU2005106871A (ru)	2002-08-14	2005-10-10	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Ингибиторы протеинкиназ и их применение
AU2003286711A1 (en)	2002-10-25	2004-05-13	Vertex Pharmaceuticals Incorporated	Indazolinone compositions useful as kinase inhibitors
US7348335B2 (en)	2002-11-05	2008-03-25	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of JAK and other protein kinases
EP1610793A2 (en)	2003-03-25	2006-01-04	Vertex Pharmaceuticals Incorporated	Thiazoles useful as inhibitors of protein kinases
JP2006522125A (ja)	2003-03-25	2006-09-28	バーテックス　ファーマシューティカルズ　インコーポレイテッド	プロテインキナーゼのインヒビターとして有用なチアゾール
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2004265288A1 (en)	2003-07-30	2005-02-24	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7320992B2 (en)	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2005039564A1 (en)	2003-10-02	2005-05-06	Vertex Pharmaceuticals Incorporated	Phthalimide compounds useful as protein kinase inhibitors
BRPI0416692A (pt) *	2003-11-19	2007-01-30	Array Biopharma Inc	inibidores heterocìclicos de mek e métodos de emprego destes
WO2005056524A2 (en)	2003-12-09	2005-06-23	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
US8057815B2 (en)	2004-04-19	2011-11-15	Portola Pharmaceuticals, Inc.	Methods of treatment with Syk inhibitors
EP1786783A1 (en)	2004-09-01	2007-05-23	Rigel Pharmaceuticals, Inc.	Synthesis of 2,4-pyrimidinediamine compounds
US7557207B2 (en)	2004-11-24	2009-07-07	Rigel Pharmaceuticals, Inc.	Spiro 2,4-pyrimidinediamine compounds and their uses
US20060128710A1 (en)	2004-12-09	2006-06-15	Chih-Hung Lee	Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
BRPI0608934A2 (pt)	2005-04-06	2010-02-17	Irm Llc	compostos e composições contendo diarilamina, e seu uso como moduladores de receptores nucleares de hormÈnios esteróides
WO2006112479A1 (ja) *	2005-04-19	2006-10-26	Kyowa Hakko Kogyo Co., Ltd.	含窒素複素環化合物
WO2006129100A1 (en)	2005-06-03	2006-12-07	Glaxo Group Limited	Novel compounds
WO2007002781A2 (en)	2005-06-28	2007-01-04	Bausch & Lomb Incorporated	Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
US20070185063A1 (en)	2005-08-23	2007-08-09	Idenix Pharmaceuticals, Inc.	Seven-membered ring nucleosides
WO2007023382A2 (en)	2005-08-25	2007-03-01	Pfizer Inc.	Pyrimidine amino pyrazole compounds, potent kinase inhibitors
CA2625109A1 (en) *	2005-10-13	2007-04-19	Glaxo Group Limited	Pyrrolopyrimidine derivatives as syk inhibitors
CA2627242A1 (en)	2005-10-31	2007-05-10	Rigel Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory disorders
US7601713B2 (en) *	2005-12-15	2009-10-13	Rigel Pharmaceuticals, Inc.	Kinase inhibitors and their uses
CN104650077A (zh)	2006-01-17	2015-05-27	沃泰克斯药物股份有限公司	适用作詹纳斯激酶抑制剂的吖吲哚类
CL2007002617A1 (es)	2006-09-11	2008-05-16	Sanofi Aventis	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2108642A1 (en)	2006-10-17	2009-10-14	Kyowa Hakko Kirin Co., Ltd.	Jak inhibitor
KR101504669B1 (ko)	2006-10-19	2015-03-20	시그날 파마소티칼 엘엘씨	헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
WO2008057402A2 (en)	2006-11-02	2008-05-15	Cytovia, Inc.	N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2078026B1 (en)	2006-11-21	2012-01-04	Rigel Pharmaceuticals, Inc.	Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
RU2009128982A (ru) *	2006-12-28	2011-02-10	Тайсо Фармасьютикал Ко., Лтд. (Jp)	Пиразолопиримидиновые соединения
US20110053953A1 (en) *	2007-02-09	2011-03-03	Abdelmalik Slassi	AZA-Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - 613
WO2008118332A2 (en)	2007-03-23	2008-10-02	Schering Corporation	Hydrazido-peptides as inhibitors of hcv ns3-protease
NZ581817A (en)	2007-06-03	2012-05-25	Univ Vanderbilt	Benzamide mglur5 positive allosteric modulators and methods of making and using same
US7705004B2 (en)	2007-08-17	2010-04-27	Portola Pharmaceuticals, Inc.	Protein kinase inhibitors
JP2009067729A (ja)	2007-09-14	2009-04-02	Kyowa Hakko Kirin Co Ltd	Ｈｓｐ９０ファミリー蛋白質阻害剤
AU2008323694A1 (en)	2007-11-07	2009-05-14	Foldrx Pharmaceuticals, Inc.	Modulation of protein trafficking
CA2710118A1 (en)	2007-12-20	2009-07-02	Cellzome Limited	Sulfamides as zap-70 inhibitors
TW200942537A (en) *	2008-02-01	2009-10-16	Irm Llc	Compounds and compositions as kinase inhibitors
WO2009102468A1 (en)	2008-02-13	2009-08-20	Cgi Pharmaceuticals, Inc.	6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
HRP20170050T1 (hr)	2008-02-22	2017-03-10	Rigel Pharmaceuticals, Inc.	Uporaba 2,4-pirimidindiamina za liječenje ateroskleroze
US8436005B2 (en)	2008-04-03	2013-05-07	Abbott Laboratories	Macrocyclic pyrimidine derivatives
EA024109B1 (ru)	2008-04-16	2016-08-31	Портола Фармасьютиклз, Инк.	Ингибиторы протеинкиназ
KR20170051521A (ko)	2008-04-16	2017-05-11	포톨라 파마슈티컬스, 인코포레이티드	ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
EA201100136A1 (ru)	2008-06-13	2011-08-30	Новартис Аг	2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
CA2732087A1 (en)	2008-08-05	2010-02-11	Boehringer Ingelheim International Gmbh	Substituted naphthyridines and their use as medicaments
EP2313406B1 (de)	2008-08-05	2015-02-25	Boehringer Ingelheim International GmbH	4-dimethylaminophenyl-substituierte napththyridine und ihre verwendung als arzneimittel
TWI453207B (zh)	2008-09-08	2014-09-21	Signal Pharm Llc	胺基三唑并吡啶，其組合物及使用其之治療方法
AU2009325133B2 (en)	2008-12-08	2016-02-04	Gilead Connecticut, Inc.	Imidazopyrazine Syk inhibitors
EP2443106A1 (en)	2009-06-18	2012-04-25	Cellzome Limited	Heterocyclylaminopyrimidines as kinase inhibitors
ES2609040T3 (es)	2009-12-17	2017-04-18	Merck Sharp & Dohme Corp.	Aminopirimidinas como inhibidores de Syk
EP2512246B1 (en)	2009-12-17	2015-09-30	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
PT2516434E (pt)	2009-12-23	2015-10-05	Takeda Pharmaceutical	Pirrolidinonas heteroaromáticas fundidas como inibidores de syk
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
EP2723739B1 (en)	2011-06-22	2016-08-24	Takeda Pharmaceutical Company Limited	Substituted 6-aza-isoindolin-1-one derivatives

2010
- 2010-12-17 PT PT108008350T patent/PT2516434E/pt unknown
- 2010-12-17 EP EP10800835.0A patent/EP2516434B1/en active Active
- 2010-12-17 UA UAA201207806A patent/UA107100C2/ru unknown
- 2010-12-17 RS RS20150544A patent/RS54180B1/sr unknown
- 2010-12-17 CN CN201080063801.2A patent/CN102753548B/zh active Active
- 2010-12-17 BR BR112012015651-9A patent/BR112012015651B1/pt not_active IP Right Cessation
- 2010-12-17 ES ES10800835.0T patent/ES2545616T3/es active Active
- 2010-12-17 EP EP20198958.9A patent/EP3825316A1/en not_active Withdrawn
- 2010-12-17 JP JP2012546092A patent/JP5658274B2/ja active Active
- 2010-12-17 EP EP18200820.1A patent/EP3489236B1/en active Active
- 2010-12-17 PL PL10800835T patent/PL2516434T3/pl unknown
- 2010-12-17 SI SI201031001T patent/SI2516434T1/sl unknown
- 2010-12-17 EA EA201290555A patent/EA021568B1/ru unknown
- 2010-12-17 AU AU2010333804A patent/AU2010333804B2/en active Active
- 2010-12-17 SG SG2012045936A patent/SG181857A1/en unknown
- 2010-12-17 NZ NZ60126710A patent/NZ601267A/en not_active IP Right Cessation
- 2010-12-17 ME MEP-2015-125A patent/ME02186B/me unknown
- 2010-12-17 CA CA2786950A patent/CA2786950C/en active Active
- 2010-12-17 MY MYPI2012002889A patent/MY159257A/en unknown
- 2010-12-17 EP EP14199188.5A patent/EP2902392B1/en active Active
- 2010-12-17 HR HRP20150878TT patent/HRP20150878T1/hr unknown
- 2010-12-17 WO PCT/US2010/061146 patent/WO2011079051A1/en not_active Ceased
- 2010-12-17 GE GEAP201012794A patent/GEP20156243B/en unknown
- 2010-12-17 DK DK10800835.0T patent/DK2516434T3/en active
- 2010-12-17 US US13/518,806 patent/US9181255B2/en active Active
- 2010-12-17 MX MX2012007402A patent/MX2012007402A/es active IP Right Grant
- 2010-12-17 MA MA35044A patent/MA33909B1/fr unknown
- 2010-12-17 PH PH1/2012/501311A patent/PH12012501311A1/en unknown
- 2010-12-17 HU HUE10800835A patent/HUE025177T2/en unknown
- 2010-12-17 PE PE2012000885A patent/PE20130188A1/es active IP Right Grant
- 2010-12-17 US US12/972,333 patent/US8440689B2/en active Active
- 2010-12-17 KR KR1020127019343A patent/KR101790255B1/ko active Active
- 2010-12-22 UY UY33151A patent/UY33151A/es not_active Application Discontinuation
- 2010-12-22 JO JOP/2010/0471A patent/JO3108B1/ar active
- 2010-12-22 AR ARP100104923 patent/AR081797A1/es unknown
- 2010-12-23 TW TW99145627A patent/TWI457339B/zh active
2012
- 2012-06-19 IL IL220509A patent/IL220509A/en active IP Right Grant
- 2012-06-21 TN TNP2012000316A patent/TN2012000316A1/en unknown
- 2012-06-25 DO DO2012000180A patent/DOP2012000180A/es unknown
- 2012-06-25 CL CL2012001745A patent/CL2012001745A1/es unknown
- 2012-07-19 CO CO12121953A patent/CO6592058A2/es active IP Right Grant
- 2012-07-19 ZA ZA2012/05428A patent/ZA201205428B/en unknown
- 2012-07-23 EC ECSP12012057 patent/ECSP12012057A/es unknown
- 2012-07-23 CR CR20120392A patent/CR20120392A/es unknown
2013
- 2013-05-02 US US13/886,032 patent/US9108970B2/en active Active
2014
- 2014-11-27 JP JP2014239677A patent/JP5968983B2/ja not_active Expired - Fee Related
2015
- 2015-07-31 US US14/814,878 patent/US20150336964A1/en not_active Abandoned
- 2015-08-17 SM SM201500199T patent/SMT201500199B/xx unknown
- 2015-08-26 CY CY20151100745T patent/CY1116736T1/el unknown
2016
- 2016-07-06 JP JP2016133849A patent/JP6196710B2/ja active Active
2017
- 2017-08-18 JP JP2017158005A patent/JP2018009017A/ja active Pending
- 2017-08-21 US US15/681,953 patent/US20180141951A1/en not_active Abandoned
2018
- 2018-12-17 JP JP2018235779A patent/JP2019056000A/ja active Pending
2019
- 2019-06-21 US US16/449,123 patent/US20220306634A1/en not_active Abandoned
2020
- 2020-06-23 JP JP2020107416A patent/JP2020164537A/ja active Pending
2022
- 2022-05-20 JP JP2022083170A patent/JP2022110135A/ja active Pending
2023
- 2023-01-12 US US18/096,392 patent/US20230295171A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2015091815A (ja)	2015-05-14
SMT201500199B (it)	2015-10-30
HK1176054A1 (en)	2013-07-19
US20130116260A1 (en)	2013-05-09
US20110152273A1 (en)	2011-06-23
EP2902392B1 (en)	2018-10-17
MX2012007402A (es)	2012-08-23
HUE025177T2 (en)	2016-02-29
US20230295171A1 (en)	2023-09-21
EP3825316A1 (en)	2021-05-26
HRP20150878T1 (xx)	2015-09-25
WO2011079051A1 (en)	2011-06-30
EP3489236B1 (en)	2020-09-30
US20180141951A1 (en)	2018-05-24
AU2010333804B2 (en)	2015-07-16
KR101790255B1 (ko)	2017-10-26
US20150336964A1 (en)	2015-11-26
MA33909B1 (fr)	2013-01-02
CR20120392A (es)	2012-12-27
PE20130188A1 (es)	2013-02-21
UA107100C2 (xx)	2014-11-25
CN102753548B (zh)	2015-03-11
TW201127839A (en)	2011-08-16
JP5968983B2 (ja)	2016-08-10
CN102753548A (zh)	2012-10-24
PL2516434T3 (pl)	2015-11-30
NZ601267A (en)	2014-03-28
AU2010333804A1 (en)	2012-07-26
EA021568B1 (ru)	2015-07-30
ES2545616T3 (es)	2015-09-14
UY33151A (es)	2011-07-29
US20220306634A1 (en)	2022-09-29
US20130245031A1 (en)	2013-09-19
SI2516434T1 (sl)	2015-10-30
JP5658274B2 (ja)	2015-01-21
PH12012501311A1 (en)	2016-07-22
JP2022110135A (ja)	2022-07-28
JO3108B1 (ar)	2017-09-20
JP2013515729A (ja)	2013-05-09
US9181255B2 (en)	2015-11-10
US9108970B2 (en)	2015-08-18
JP2020164537A (ja)	2020-10-08
TN2012000316A1 (en)	2013-12-12
GEP20156243B (en)	2015-02-10
AR081797A1 (es)	2012-10-24
BR112012015651B1 (pt)	2021-10-26
CA2786950A1 (en)	2011-06-30
CA2786950C (en)	2019-01-15
KR20120124417A (ko)	2012-11-13
CY1116736T1 (el)	2017-03-15
EP2516434A1 (en)	2012-10-31
EP3489236A1 (en)	2019-05-29
ECSP12012057A (es)	2012-10-30
CO6592058A2 (es)	2013-01-02
ZA201205428B (en)	2013-09-25
JP6196710B2 (ja)	2017-09-13
EA201290555A1 (ru)	2013-01-30
JP2018009017A (ja)	2018-01-18
EP2516434B1 (en)	2015-05-27
SG181857A1 (en)	2012-07-30
US8440689B2 (en)	2013-05-14
JP2017008052A (ja)	2017-01-12
JP2019056000A (ja)	2019-04-11
DK2516434T3 (en)	2015-08-31
BR112012015651A2 (pt)	2017-09-26
EP2902392A1 (en)	2015-08-05
TWI457339B (zh)	2014-10-21
PT2516434E (pt)	2015-10-05
DOP2012000180A (es)	2012-09-15
MY159257A (en)	2016-12-30
RS54180B1 (sr)	2015-12-31
ME02186B (me)	2016-02-20
IL220509A (en)	2016-07-31

Publication	Publication Date	Title
CL2012001745A1 (es)	2014-07-18	Compuestos derivados de pirrolidinonas heteroaromáticas fusionadas con actividad inhibitoria de tirosina quinasa esplénica; composición farmacéutica que los comprende; uso en el tratamiento de la rinitis alérgica, asma, dermatitis atópica, lupus eritematoso sistémico, artritis reumatoide, psoriasis, epoc, entre otras
CY2024019I2 (el)	2024-12-13	Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)- 5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
CL2008001632A1 (es)	2009-10-16	Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CL2016002888A1 (es)	2017-05-12	Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras.
SMT201500097B (it)	2015-07-09	Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CL2014002732A1 (es)	2015-01-23	Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras.
CL2008000307A1 (es)	2008-05-30	Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
CL2014001664A1 (es)	2014-10-03	Compuestos derivados de 2-([1,4]dioxan-2-ilmetoxi)-6,7-dihidropirimido[6,1-a]isoquinolin-4-ona, antagonistas del receptor gpr84; composicion farmaceutica; metodo de tratamiento o profilaxis; y uso en el tratamiento o profilaxis de afecciones inflamatorias tales como artritis reumatoide, vasculitis, asma y psoriasis, entre otras.
CL2012001807A1 (es)	2012-10-12	Compuestos derivados de naftiridina, inhibidores de syk quinasa; compuestos intermediarios, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades tales como rinitis alergica, asma, epoc, lupus eritematoso, urticaria/angioedema, entre otros.
CL2014003031A1 (es)	2015-03-06	Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
CL2015002301A1 (es)	2016-06-03	Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
CL2014002412A1 (es)	2015-03-06	Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
SMT201600144B (it)	2016-07-01	Nuovi derivati eterociclici e loro uso nel trattamento di disturbi neurologici
BR112013013790A2 (pt)	2016-09-13	compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
CL2015001249A1 (es)	2015-07-31	Compuestos derivados de piridilo sustituidos con heteroarilo, como moduladores de cinasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como enfermedad de crohn, lupus eritematoso sistemico, esclerosis multiple, gota y artritis gotosa.
CL2013003472A1 (es)	2014-08-18	Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
CL2014000350A1 (es)	2014-08-22	Compuestos 1-oxo-1h-(ftalazin o isoquinolin)-2-il sustituidos, inhibidores de la tirosina-quinasa de bruton (btk); composicion farmaceutica; metodo para el tratamiento de un estado patologico inflamatorio y/o autoinmune, artritis resumatoide o asma; y uso para tratar un estado patologico inflamatorio y/o autoinmune.
HUE055618T2 (hu)	2021-12-28	2-amino-N-(piperidin-1-il-piridin-3-il)-pirazolo-[1,5-alfa]-pirimidin-3-karboxamid, mint atr-kináz inhibítoraként használható vegyület
CL2010001637A1 (es)	2011-07-15	Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
EP2834822A4 (en)	2015-11-18	POROUS ELECTRODE STRUCTURE
CL2008000936A1 (es)	2008-10-03	Derivados de piridina y pirimidina, antagonistas del mglur2; composicion farmaceutica que los contiene; procedimiento de preparacion; y su uso en el tratamiento y profilaxis de trastornos neurologigos agudos y/o cronicos, tales como psicosis, esquizo
CL2015002030A1 (es)	2015-12-11	Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
HUE036248T2 (hu)	2018-06-28	Aminoglükozidok és alkalmazásaik genetikai rendellenességek kezelésére
CL2011001427A1 (es)	2011-10-21	Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2014003325A1 (es)	2015-04-24	Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer